Partner Article
Railpen Grows Cambridge Portfolio with Acquisition of Coral Park Trading Estate
Railpen, one of the largest pension managers in the UK, has purchased Coral Park Trading Estate in Cambridge. Coral Park comprises nine units totalling 50,474 sq ft and is fully let to tenants such as Halfords, Wolseley and Royal Mail, offering a secure income stream with that will deliver long-term returns for Railpen’s members.
The acquisition increases Railpen’s Cambridge portfolio, which includes the adjacent Cambridge Retail Park and The Beehive Centre. In September last year, Railpen also acquired Botanic Place, a 309,000 sq ft prime office development midway between the city’s train station and the city centre to complement its Devonshire Gardens mixed-use development and the existing office ownerships - 21 Station Road and One The Square.
Alastair Dawson, Senior Asset Manager at Railpen, said: “Coral Park Trading Estate is a strategic purchase that consolidates our already significant ownership in Cambridge, a market we view as an important, cross-sector, UK location for our portfolio. Cambridge possesses a number of unique positive attributes, including a thriving knowledge-led economy, a supportive local authority who share our commitment to sustainable development, and sustained occupier demand.”
DTRE represented Railpen.
This was posted in Bdaily's Members' News section by Nick Thornton .
Enjoy the read? Get Bdaily delivered.
Sign up to receive our popular morning National email for free.
Improving North East transport will improve lives
Unlocking investment potential before year end
Give us certainty to deliver better homes
Hormuz: Safe passage - not insurance - the issue
Don't get caught out by employment law change
When literacy thrives, our businesses thrive too
Building a more diverse construction sector
The value of using data like a Premier League club
Raising the bar to boost North East growth
Navigating the messy middle of business growth
We must make it easier to hire young people
Why community-based care is key to NHS' future